Heparin-Induced Thrombocytopenia
Introduction to Heparin-Induced Thrombocytopenia
- Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated condition that can occur in up to 13.1% of patients treated with unfractionated heparin (UFH), according to the American Heart Association, and is associated with an antibody-mediated reaction that can cause arterial or venous thrombosis 1
- The European Heart Journal reports that heparin products, including UFH and low-molecular-weight heparins (LMWH), can cause HIT, occurring in up to 15% of patients treated with UFH, less frequent with LMWH 2, 3
Risk and Timing
- The American Society of Anesthesiologists notes that HIT typically occurs between days 5-14 of therapy, but can occur earlier in patients with recent heparin exposure, with a critical timing of 5-10 days after starting heparin 4
- HIT can occur within 24 hours in patients with recent heparin exposure, as stated by the American Society of Anesthesiologists 4
- The risk of HIT is higher with UFH than LMWH, and fondaparinux does not cause HIT, as reported by the European Heart Journal 3
Patient Risk Factors
- Multiple myeloma patients on IMiDs (thalidomide and lenalidomide) have an increased risk of thrombotic events, according to the European Society for Medical Oncology 5
- Patients with a history of heparin exposure are at increased risk of developing HIT, as implied by the American Society of Anesthesiologists 4
Severity Assessment
- The American Society of Anesthesiologists reports that HIT typically causes moderate thrombocytopenia, with platelet count rarely falling below 20 G/L in HIT 4
- The 4T score can be used to assess the severity of thrombocytopenia, considering thrombocytopenia severity, timing of platelet count fall, thrombosis or other sequelae, and other causes of thrombocytopenia, with a definition of heparin-induced thrombocytopenia being a platelet count <100 × 10⁹/L or >50% decrease from baseline 4, 2
Diagnosis
- The American Society of Anesthesiologists recommends using the 4T score for suspected HIT, which includes thrombocytopenia severity, timing of platelet count fall, thrombosis or other sequelae, and other causes of thrombocytopenia 4
- The following table summarizes the 4T score for suspected heparin-induced thrombocytopenia:
| Category | 2 Points | 1 Point | 0 Points |
|---|---|---|---|
| Thrombocytopenia | Platelet count fall ≥50% and nadir ≥20 × 10⁹/L | Platelet count fall ≥50% and nadir <20 × 10⁹/L | Platelet count fall <50% |
| Timing | Clear onset between days 5-10 | Onset after day 10 or unclear | Onset before day 5 |
| Thrombosis | New thrombosis or skin necrosis | Progressive or recurrent thrombosis | None |
| Other causes | No other cause for thrombocytopenia | Possible other cause for thrombocytopenia | Definite other cause for thrombocytopenia |
- Other medications, such as vancomycin, sulfonamides, and penicillin derivatives, can also cause drug-induced thrombocytopenia, according to the American Society of Hematology 6
- Quinine/Quinidine derivatives and glycoprotein IIb/IIIa inhibitors can cause thrombocytopenia through immune-mediated destruction of platelets, as noted by the Journal of Thrombosis and Haemostasis, Blood, and the American College of Cardiology 6, 7, 8
Management
- The American College of Clinical Pharmacy recommends immediate discontinuation of the suspected causative drug, platelet transfusions for active bleeding or severe thrombocytopenia, and alternative anticoagulation if heparin-induced thrombocytopenia is suspected 6
- Management of heparin-induced thrombocytopenia involves immediate discontinuation of all heparin products and initiation of alternative anticoagulation, such as argatroban, bivalirudin, or fondaparinux, as recommended by Chest 2
- Monitoring of platelet counts every 2-3 days from day 4 to 14 is recommended for patients receiving heparin with risk >1%, as suggested by Chest, and daily monitoring is necessary for patients on glycoprotein IIb/IIIa inhibitors, as recommended by the Journal of the American College of Cardiology 2, 9
- Documentation of drug reactions is crucial to prevent re-exposure to causative agents, as emphasized by the American College of Cardiology 2
- Clinicians should remain vigilant about monitoring platelet counts in patients on any medication regimen, especially those with risk factors for thrombocytopenia or bleeding, and consider discontinuation of other medications with known associations to thrombocytopenia, as noted by the American College of Cardiology 8